Drug Trial Radar · NCT01600105
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Oct 2010
Primary completion
Jul 31, 2017
Study completion Jul 31, 2017
Sponsor
- Lead sponsor
- Bachir TaouliAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Patients with chronic liver disease are at high risk of developing liver scarring (fibrosis), with ultimate risks of cirrhosis and liver cancer that may require liver transplant. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR diffusion, perfusion and elastography) to assess the degree of liver damage in patients with chronic liver disease. These techniques combined could reach high diagnostic performance for detection of liver fibrosis; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.
Conditions
- Chronic Liver Disease
Interventions
Perfusion MRIDrug
1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PV FlowTime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
- PV VelocityTime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
- LS-MRE for Sub-Study ITime frame: Fasting State Scan (an average of 15 min) and Postprandial State Scan (an average of 15 min)
- True Diffusion Parameter (D)Time frame: Fasting State Multiparametric MRI Scan (an average of 60 min) Scan
- LS-MRE Fibrosis State for Sub Study IITime frame: Fasting State Multiparametric MRI Scan (an average of 60 min)
- LS-TETime frame: Fasting transient elastography, average duration 10 min
- MTTTime frame: Fasting State Multiparametric MRI Scan (an average of 60 min)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.